Voyager Therapeutics (VYGR) EBT (2014 - 2026)

Voyager Therapeutics has disclosed EBT across 13 years of filings, most recently posting -$24.5 million for Q2 2026.

• In Q2 2026, EBT rose 26.72% year-over-year to -$24.5 million; the TTM figure through Jun 2026 stood at -$107.6 million (changed 0.32% YoY), while the FY2025 annual figure was -$119.6 million, down 85.86% from the prior year.
• EBT came in at -$24.5 million for Q2 2026 at Voyager Therapeutics, up from -$27.9 million in the prior quarter.
• In the past five years, EBT ranged from a high of $124.7 million in Q1 2023 to a low of -$33.9 million in Q4 2024.
• Average EBT over 5 years is -$8.3 million, with a median of -$22.9 million recorded in 2022.
• Year-over-year, EBT slumped 566.69% in 2022 and soared 685.15% in 2023.
• Over 5 years, EBT stood at -$23.6 million in 2022, then jumped by 342.34% to $57.2 million in 2023, then sank by 159.25% to -$33.9 million in 2024, then rose by 19.13% to -$27.4 million in 2025, then rose by 10.81% to -$24.5 million in 2026.
• Per Business Quant data, the three most recent EBT figures were -$24.5 million in Q2 2026, -$27.9 million in Q1 2026, and -$27.4 million in Q4 2025.